BeyondSpring (BYSI) Stock Is a Good Investment, Wait for Better Price
An Overview of Spectrum Pharmaceuticals’ Drug Pipeline
Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.
What Viking Therapeutics’ Valuation Trend Indicates
In October, of the seven analysts covering Viking Therapeutics, one has given its stock a “strong buy” rating.
Chart in Focus: Spectrum Pharmaceuticals’ Financials
In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.
Analysts’ Recommendations for Spectrum Pharmaceuticals
Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.